Skip to main content
Dr. Lal Pathlabs Limited logo

Dr. Lal Pathlabs Limited — Investor Relations & Filings

Ticker · LALPATHLAB ISIN · INE600L01024 LEI · 984500E8E9CY102B9718 BSE.NS Human health and social work activities
Open in API
Filings indexed 1,098 across all filing types
Latest filing 2022-11-08 Regulatory Filings
Country IN India
Listing BSE.NS LALPATHLAB

About Dr. Lal Pathlabs Limited

https://www.lalpathlabs.com/

Dr. Lal Pathlabs Limited is a provider of diagnostic and related healthcare tests and services. The company offers a comprehensive range of clinical laboratory tests and profiles used for prediction, early detection, diagnostic screening, confirmation, and monitoring of diseases. Its service portfolio encompasses pathology, including biochemistry, hematology, clinical pathology, histopathology, and molecular diagnostics, as well as radiology services such as X-ray, ultrasound, and CT scans. The organization operates an extensive network of laboratories, patient service centers, and pick-up points, utilizing advanced automated systems and standardized processes. Key offerings include specialized wellness packages and home sample collection. The company maintains high quality standards through international and national accreditations, serving a diverse patient base and healthcare providers with a focus on accuracy and timely reporting.

Recent filings

Filing Released Lang Actions
Recording of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a short announcement dated November 8, 2022, addressed to stock exchanges, informing them about the availability of the audio recording of a conference call with investors and analysts for Q2 & H1-FY23. It references the SEBI Listing Obligations and Disclosure Requirements Regulations, indicating a regulatory compliance announcement. The document does not contain the transcript or detailed financial data but only provides a link to the audio recording on the company's website. Given the short length (1480 characters) and the nature of the content, this is not the conference call transcript itself but an announcement about the availability of the recording. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a Call Transcript (CT) or Interim Report (IR).
2022-11-08 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled as an "Investors Presentation on Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2022." It contains detailed financial highlights, key performance indicators, and management commentary for Q2 and H1 FY23. The content includes revenue, EBITDA, PAT, and other financial metrics, along with forward-looking statements and disclaimers typical of investor presentations. The document is approximately 15,000 characters long, indicating it is a full presentation rather than a brief announcement. There is no indication that this is a full annual report or an audit report, nor is it a transcript or regulatory filing. The presence of slides, tables, and detailed financial data aimed at investors confirms it is an Investor Presentation (IP).
2022-11-08 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated November 8, 2022, announcing unaudited financial results for the quarter and half year ended September 30, 2022. It contains summarized financial highlights, revenue figures, EBITDA, PBT, PAT, and EPS for Q2 FY 2022-23 compared to the previous year. The document is titled as a 'Press Release' and is addressed to stock exchanges, indicating it is an initial announcement of quarterly financial results. It does not contain full financial statements or detailed analysis typical of an Interim/Quarterly Report (IR), but rather key financial highlights. Therefore, it fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results with key highlights only. Q2 2023
2022-11-08 English
Appointment
Regulatory Filings
2022-11-08 English
Outcome of Board Meeting
Regulatory Filings
2022-11-08 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Call Transcript Classification · 95% confidence The document is an invitation and intimation of a conference call scheduled for November 8, 2022, to discuss the Q2 & H1 FY23 financial and operating performance of Dr. Lal PathLabs Limited. It references the upcoming earnings announcement and provides details for investors and analysts to join the call. There are no actual financial statements or detailed financial analysis included in the text. The document is primarily an announcement of the conference call event related to earnings results, not the earnings release itself or a transcript. Therefore, the document fits the category of a Call Transcript (CT) invitation or announcement. However, since it is only an invitation and not the transcript, the best fitting category is Call Transcript (CT) as it relates to the conference call content and context.
2022-11-01 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.